Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.42)
# 369
Out of 4,761 analysts
213
Total ratings
44.62%
Success rate
28.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SUPN Supernus Pharmaceuticals | Downgrades: Neutral | $57 → $36 | $33.05 | +8.93% | 1 | Feb 19, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $76 → $113 | $50.69 | +122.92% | 18 | Feb 3, 2025 | |
| CLDX Celldex Therapeutics | Reiterates: Overweight | $67 | $22.46 | +198.31% | 15 | Jan 29, 2025 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $118 | $42.59 | +177.06% | 17 | Jan 22, 2025 | |
| FOLD Amicus Therapeutics | Reiterates: Overweight | $21 | $9.19 | +128.51% | 7 | Jan 15, 2025 | |
| ETNB 89bio | Reiterates: Overweight | $29 | $11.06 | +162.21% | 13 | Jan 2, 2025 | |
| AQST Aquestive Therapeutics | Initiates: Overweight | $17 | $3.01 | +464.78% | 1 | Dec 17, 2024 | |
| ESPR Esperion Therapeutics | Initiates: Overweight | $8 | $1.82 | +339.56% | 1 | Dec 17, 2024 | |
| QURE uniQure | Maintains: Overweight | $28 → $58 | $12.84 | +351.71% | 9 | Dec 10, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $15 → $25 | $20.09 | +24.44% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $4.18 | +163.16% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $1.61 | +334.78% | 15 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $30 | $15.00 | +100.00% | 4 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $152 → $167 | $106.28 | +57.13% | 13 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.78 | +211.42% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $85 | $54.53 | +55.88% | 7 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $2.85 | +145.61% | 9 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $2.98 | +369.80% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $46.13 | +45.24% | 5 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $3.54 | +267.23% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $15.84 | +26.26% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.85 | - | 3 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.47 | +970.43% | 3 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.17 | +1,694.87% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $0.68 | +787.57% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.56 | +1,182.05% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $2.68 | +758.21% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $2.95 | +30,408.47% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $41 | $0.80 | +5,031.41% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $4.51 | +8,769.18% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $3.48 | +2,342.53% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $0.17 | +40,907.62% | 1 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $7.66 | +2,249.87% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $1.71 | +2,531.58% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $0.68 | +1,517.65% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.57 | +3,721.66% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.42 | +6,251.45% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $2.70 | +93,126.30% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.96 | +16,587.53% | 1 | Jan 9, 2020 |
Supernus Pharmaceuticals
Feb 19, 2025
Downgrades: Neutral
Price Target: $57 → $36
Current: $33.05
Upside: +8.93%
PTC Therapeutics
Feb 3, 2025
Maintains: Overweight
Price Target: $76 → $113
Current: $50.69
Upside: +122.92%
Celldex Therapeutics
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $22.46
Upside: +198.31%
Ultragenyx Pharmaceutical
Jan 22, 2025
Reiterates: Overweight
Price Target: $118
Current: $42.59
Upside: +177.06%
Amicus Therapeutics
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $9.19
Upside: +128.51%
89bio
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $11.06
Upside: +162.21%
Aquestive Therapeutics
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $3.01
Upside: +464.78%
Esperion Therapeutics
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $1.82
Upside: +339.56%
uniQure
Dec 10, 2024
Maintains: Overweight
Price Target: $28 → $58
Current: $12.84
Upside: +351.71%
Rigel Pharmaceuticals
Dec 10, 2024
Maintains: Neutral
Price Target: $15 → $25
Current: $20.09
Upside: +24.44%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $4.18
Upside: +163.16%
Nov 14, 2024
Reiterates: Overweight
Price Target: $7
Current: $1.61
Upside: +334.78%
Nov 14, 2024
Maintains: Overweight
Price Target: $25 → $30
Current: $15.00
Upside: +100.00%
Nov 7, 2024
Upgrades: Overweight
Price Target: $152 → $167
Current: $106.28
Upside: +57.13%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.78
Upside: +211.42%
Oct 15, 2024
Reiterates: Overweight
Price Target: $85
Current: $54.53
Upside: +55.88%
Oct 1, 2024
Reiterates: Overweight
Price Target: $7
Current: $2.85
Upside: +145.61%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $2.98
Upside: +369.80%
Sep 20, 2024
Reiterates: Overweight
Price Target: $67
Current: $46.13
Upside: +45.24%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $3.54
Upside: +267.23%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $15.84
Upside: +26.26%
Sep 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.85
Upside: -
May 31, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.47
Upside: +970.43%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.17
Upside: +1,694.87%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $0.68
Upside: +787.57%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.56
Upside: +1,182.05%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $2.68
Upside: +758.21%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $2.95
Upside: +30,408.47%
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $0.80
Upside: +5,031.41%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $4.51
Upside: +8,769.18%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $3.48
Upside: +2,342.53%
Feb 28, 2022
Initiates: Overweight
Price Target: $70
Current: $0.17
Upside: +40,907.62%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $7.66
Upside: +2,249.87%
May 26, 2021
Initiates: Overweight
Price Target: $45
Current: $1.71
Upside: +2,531.58%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $0.68
Upside: +1,517.65%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.57
Upside: +3,721.66%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.42
Upside: +6,251.45%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $2.70
Upside: +93,126.30%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.96
Upside: +16,587.53%